Pricing Log in Create free account

Cullinan Therapeutics, Inc. (CGEM) vs Zevra Therapeutics, Inc. (ZVRA)

Cullinan Therapeutics, Inc. and Zevra Therapeutics, Inc. are both Biotechnology companies. Cullinan Therapeutics, Inc. and Zevra Therapeutics, Inc. are of similar size ($730.4M and $705.1M). Cullinan Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Zevra Therapeutics, Inc. trades at 9.2×. Zevra Therapeutics, Inc. has the higher net margin (50.7% vs 0.00%) and the higher return on invested capital (129.5% vs 0.00%). Across the 12 metrics below, Zevra Therapeutics, Inc. leads on 9 and Cullinan Therapeutics, Inc. on 3.

Valuation

Metric CGEM ZVRA Biotechnology median
P/E n/m 9.22 11.58
P/S n/m 4.76 9.61
P/B 2.16 2.94 2.26
Price to free cash flow n/m 8.07 26.41
EV/EBITDA n/m 6.80 0.72
EV/Sales n/m 4.11 9.43
Earnings yield (27.39%) 10.85% (32.28%)
Free cash flow yield (22.88%) 12.39% (22.27%)

Profitability

Metric CGEM ZVRA Biotechnology median
Gross margin — 95.44% 68.81%
Operating margin 0.00% 60.78% 0.00%
Net margin 0.00% 50.73% 0.00%
Free cash flow margin 0.00% 58.93% 0.00%
Return on equity (50.30%) 40.29% (50.30%)
Return on assets (46.30%) 25.69% (45.47%)
Return on invested capital 0.00% 129.48% 0.00%

Growth

Metric CGEM ZVRA Biotechnology median
Revenue growth (TTM) — 75.10% 6.78%
EPS growth (last fiscal year) (20.86%) 159.21% 29.88%
Revenue growth, 5-year CAGR — 51.62% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CGEM ZVRA Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 8.42 5.46 4.74
Net debt to EBITDA 1.57 39.03 1.01

Dividend

Metric CGEM ZVRA Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric CGEM ZVRA Biotechnology median
Market cap 730.42m 705.13m 168.63m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack